The Next Evolution of Hereditary Cancer Genetic Testing Service Delivery: A Descriptive Study of a Primary Collaborative Care Model for Telegenetics

Clinical genetic testing demand has increased in the era of precision medicine. However, availability of cancer genetic services remains limited in the US, prompting a rise in telehealth delivery. This report describes the Penn Telegenetics Program experience using a local healthcare provider collaborative model. From 2018-2025, 473 providers (89.4%) successfully registered. Providers were predominately MD/DO licensed (85.0%). Family medicine was the most frequent speciality (54.3%), followed by internal medicine (20.9%) and clinical oncology (11.8%). Most providers were in suburban locations by zip codes (56.2%), 20.1% were in rural zip codes. Only 56 providers declined collaboration (10.6%); the most common reasons reported were preferring local genetic services (22.5%) and not being comfortable as the ordering provider (22.5%). Our data demonstrate that most local providers are willing to collaborate with a centralized telegenetics program. Refining procedures to increase collaborative care and engagement may provide opportunities to increase access to cancer genetic testing.